Vanguard Group Inc Travere Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,994,283 shares of TVTX stock, worth $104 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,994,283

Previous 5,014,020 19.55%

Holding current value

$104 Million

Previous $89.9 Million 1.26%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$13.49 - $21.54 $13.2 Million - $21.1 Million	980,263 Added 19.55%	5,994,283 $88.7 Million
Q1 2025 May 09, 2025	SELL	$17.07 - $23.75 $29.5 Million - $41 Million	-1,728,145 Reduced 25.63%	5,014,020 $89.9 Million
Q4 2024 Feb 11, 2025	SELL	$13.65 - $19.85 $2.18 Million - $3.18 Million	-159,985 Reduced 2.32%	6,742,165 $117 Million
Q3 2024 Nov 13, 2024	BUY	$7.89 - $15.21 $2.23 Million - $4.3 Million	282,394 Added 4.27%	6,902,150 $96.6 Million
Q2 2024 Aug 13, 2024	BUY	$5.26 - $8.28 $1.86 Million - $2.93 Million	353,927 Added 5.65%	6,619,756 $54.4 Million
Q1 2024 May 10, 2024	BUY	$7.18 - $9.82 $5.39 Million - $7.37 Million	750,686 Added 13.61%	6,265,829 $48.3 Million
Q4 2023 Feb 14, 2024	BUY	$5.44 - $9.5 $4.61 Million - $8.05 Million	847,685 Added 18.16%	5,515,143 $49.6 Million
Q3 2023 Nov 14, 2023	BUY	$7.64 - $17.25 $3.52 Million - $7.94 Million	460,176 Added 10.94%	4,667,458 $41.7 Million
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $3.41 Million - $5.03 Million	222,688 Added 5.59%	4,207,282 $64.6 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $8.36 Million - $10.7 Million	469,148 Added 13.35%	3,984,594 $89.6 Million
Q4 2022 Feb 10, 2023	BUY	$18.47 - $26.14 $2.47 Million - $3.5 Million	133,836 Added 3.96%	3,515,446 $73.9 Million
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $1.16 Million - $1.45 Million	50,791 Added 1.52%	3,381,610 $83.3 Million
Q2 2022 Aug 12, 2022	SELL	$20.94 - $30.01 $10.8 Million - $15.5 Million	-516,716 Reduced 13.43%	3,330,819 $80.7 Million
Q1 2022 May 13, 2022	SELL	$23.61 - $30.6 $787,110 - $1.02 Million	-33,338 Reduced 0.86%	3,847,535 $99.2 Million
Q4 2021 Feb 14, 2022	BUY	$24.34 - $31.17 $374,641 - $479,768	15,392 Added 0.4%	3,880,873 $120 Million
Q3 2021 Nov 12, 2021	BUY	$12.98 - $25.03 $398,810 - $769,046	30,725 Added 0.8%	3,865,481 $93.7 Million
Q2 2021 Aug 13, 2021	BUY	$14.11 - $26.4 $54.1 Million - $101 Million	3,834,756 New	3,834,756 $55.9 Million

Others Institutions Holding TVTX

# of Institutions

230

Shares Held

102M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Travere Therapeutics, Inc. Transaction History